Drugging MYCN oncogenic signalling through the MYCN-PA2G4 binding interface.
暂无分享,去创建一个
M. Fischer | A. Oberthuer | M. Parker | G. Perini | Bing Liu | J. Fletcher | J. Holien | M. Gorman | C. Mayoh | J. McCarroll | M. Haber | M. Norris | S. Hüttelmaier | M. Fischer | W. C. Gustafson | G. Marshall | B. W. Stevenson | J. Koach | B. Cheung | Larissa Doughty | M. Fischer | J. Bell | Tao Liu | Shizhen Zhu | A. Gifford | Hassina Massudi | Daniel R. Carter | Xiaoling Zhang | G. Milazzo | Jayne E. Murray | Janith A. Seneviratne | Olivia C Ciampa | Mika Herath | Bryce Keenan | Taylor Lim | Brendan W. Stevenson | W. Gustafson | B. Stevenson
[1] Giovanna Ambrosini,et al. PWMScan: a fast tool for scanning entire genomes with a position-specific weight matrix , 2018, Bioinform..
[2] Donald R. Polaski,et al. Enhancer invasion shapes MYCN-dependent transcriptional amplification in neuroblastoma , 2018, Nature Genetics.
[3] J. Mao,et al. Distinct Interactions of EBP1 Isoforms with FBXW7 Elicits Different Functions in Cancer. , 2017, Cancer research.
[4] Hu Li,et al. Critical Role for GAB2 in Neuroblastoma Pathogenesis through the Promotion of SHP2/MYCN Cooperation. , 2017, Cell reports.
[5] S. Moody,et al. Pa2G4 is a novel Six1 co-factor that is required for neural crest and otic development. , 2017, Developmental biology.
[6] M. Eilers,et al. Structural basis of N-Myc binding by Aurora-A and its destabilization by kinase inhibitors , 2016, Proceedings of the National Academy of Sciences.
[7] G. Qing,et al. Polo-like Kinase-1 Regulates Myc Stabilization and Activates a Feedforward Circuit Promoting Tumor Cell Survival. , 2016, Molecular cell.
[8] A. Califano,et al. HAUSP deubiquitinated and stabilizes N-Myc in neuroblastoma , 2016, Nature Medicine.
[9] D. Goldstein,et al. A Rationally Optimized Nanoparticle System for the Delivery of RNA Interference Therapeutics into Pancreatic Tumors in Vivo. , 2016, Biomacromolecules.
[10] B. Carver. Defining and Targeting the Oncogenic Drivers of Neuroendocrine Prostate Cancer. , 2016, Cancer cell.
[11] F. Speleman,et al. Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma , 2015, Science Translational Medicine.
[12] Dongmei Zhang,et al. ErbB3 binding protein 1 (EBP1) participates in the regulation of intestinal inflammation via mediating Akt signaling pathway. , 2015, Molecular immunology.
[13] Jee-Yin Ahn,et al. P42 Ebp1 functions as a tumor suppressor in non-small cell lung cancer , 2015, BMB reports.
[14] Erin F. Simonds,et al. Drugging MYCN through an allosteric transition in Aurora kinase A. , 2014, Cancer cell.
[15] L. Mao,et al. Ebp1 activates podoplanin expression and contributes to oral tumorigenesis , 2014, Oncogene.
[16] A. Biankin,et al. Histone deacetylase 5 blocks neuroblastoma cell differentiation by interacting with N-Myc , 2014, Oncogene.
[17] S. Lowe,et al. A common functional consequence of tumor-derived mutations within c-MYC , 2014, Oncogene.
[18] Tao Liu,et al. Histone deacetylase 2 and N-Myc reduce p53 protein phosphorylation at serine 46 by repressing gene transcription of tumor protein 53-induced nuclear protein 1 , 2014, Oncotarget.
[19] Björn Usadel,et al. Trimmomatic: a flexible trimmer for Illumina sequence data , 2014, Bioinform..
[20] Jerome Wielens,et al. Oncogenic protein interfaces: small molecules, big challenges , 2014, Nature Reviews Cancer.
[21] W. Weiss,et al. The prenatal origins of cancer , 2014, Nature Reviews Cancer.
[22] H. R. Ko,et al. P42 Ebp1 regulates the proteasomal degradation of the p85 regulatory subunit of PI3K by recruiting a chaperone-E3 ligase complex HSP70/CHIP , 2014, Cell Death and Disease.
[23] C. Marcelle,et al. ErbB3 binding protein-1 (Ebp1) controls proliferation and myogenic differentiation of muscle stem cells. , 2014, Developmental biology.
[24] J. Maris,et al. Children's Oncology Group's 2013 blueprint for research: Neuroblastoma , 2013, Pediatric blood & cancer.
[25] F. Westermann,et al. Hox-C9 activates the intrinsic pathway of apoptosis and is associated with spontaneous regression in neuroblastoma , 2013, Cell Death and Disease.
[26] A. Biankin,et al. The histone deacetylase SIRT2 stabilizes Myc oncoproteins , 2012, Cell Death and Differentiation.
[27] Matthew S. Tremblay,et al. Small-molecule inducer of β cell proliferation identified by high-throughput screening. , 2013, Journal of the American Chemical Society.
[28] J. Maris,et al. Pediatric Phase I Trial and Pharmacokinetic Study of MLN8237, an Investigational Oral Selective Small-Molecule Inhibitor of Aurora Kinase A: A Children's Oncology Group Phase I Consortium Study , 2012, Clinical Cancer Research.
[29] D. Neuberg,et al. Activated ALK collaborates with MYCN in neuroblastoma pathogenesis. , 2012, Cancer cell.
[30] Jee-Yin Ahn,et al. Long isoform of ErbB3 binding protein, p48, mediates protein kinase B/Akt-dependent HDM2 stabilization and nuclear localization. , 2012, Experimental cell research.
[31] A. Biankin,et al. SIRT1 Promotes N-Myc Oncogenesis through a Positive Feedback Loop Involving the Effects of MKP3 and ERK on N-Myc Protein Stability , 2011, PLoS genetics.
[32] D. Nam,et al. Negative regulation of p53 by the long isoform of ErbB3 binding protein Ebp1 in brain tumors. , 2010, Cancer research.
[33] F. Stossi,et al. Transcriptional upregulation of histone deacetylase 2 promotes Myc-induced oncogenic effects , 2010, Oncogene.
[34] Roland Eils,et al. Prognostic impact of gene expression-based classification for neuroblastoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] K. Matthay,et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] G. Marshall,et al. The critical role of the class III histone deacetylase SIRT1 in cancer. , 2009, Cancer research.
[37] R. Beijersbergen,et al. Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. , 2009, Cancer cell.
[38] D. Brat,et al. Human BRE1 is an E3 ubiquitin ligase for Ebp1 tumor suppressor. , 2008, Molecular biology of the cell.
[39] Zhenqiu Liu,et al. Bmc Cell Biology Alterations in Cell Growth and Signaling in Erbb3 Binding Protein-1 (ebp1) Deficient Mice , 2022 .
[40] E. Hurt,et al. The crystal structure of Ebp1 reveals a methionine aminopeptidase fold as binding platform for multiple interactions , 2007, FEBS letters.
[41] Jee-Yin Ahn,et al. Ebp1 isoforms distinctively regulate cell survival and differentiation. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[42] Jee-Yin Ahn,et al. Nuclear Akt associates with PKC‐phosphorylated Ebp1, preventing DNA fragmentation by inhibition of caspase‐activated DNase , 2006, The EMBO journal.
[43] Laxmikant V. Kalé,et al. Scalable molecular dynamics with NAMD , 2005, J. Comput. Chem..
[44] A. Hamburger,et al. Specificity and heregulin regulation of Ebp1 (ErbB3 binding protein 1) mediated repression of androgen receptor signalling , 2004, British Journal of Cancer.
[45] A. Peaston,et al. Mechanisms of embryonal tumor initiation: distinct roles for MycN expression and MYCN amplification. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[46] B. Clurman,et al. The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[47] G. Brodeur. Neuroblastoma: biological insights into a clinical enigma , 2003, Nature Reviews Cancer.
[48] A. Hamburger,et al. Regulation of the ErbB3 binding protein Ebp1 by Protein Kinase C , 2001, Molecular and Cellular Endocrinology.
[49] G. Mohapatra,et al. Targeted expression of MYCN causes neuroblastoma in transgenic mice , 1997, The EMBO journal.
[50] K Schulten,et al. VMD: visual molecular dynamics. , 1996, Journal of molecular graphics.
[51] E. Jost,et al. Molecular cloning of a murine cDNA encoding a novel protein, p38-2G4, which varies with the cell cycle. , 1995, Experimental cell research.